Pet Medical Care Division

Preliminary Clinical Trial Case

Canine Right Hock Joint

Malignant Soft Tissue Sarcoma

Object Animal：Dog

Breed： Mix

Name：Caddie

Gender：Female

Age：13 years old

Weigth：13~15kg

Diagnosis: Malignant soft tissue sarcoma on right hock joint.

Case background:

During Caddie’s regular health examination conducted at an animal hospital in Penghu in early 2020, tumor hyperplasia was found on her right hock joint. After evaluation by the veterinarian, it was suggested that the owner transferred Caddie to Evergreen Animal Hospital in Wanhua District on Taiwan Island for further diagnosis and treatment. After histopathological biopsy at Evergreen Animal Hospital, it was confirmed to be malignant soft tissue sarcoma.

Gongwin Biopharm Co., Ltd. started the Pet Drug Project in December 2018, and obtained the approval from the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan (Prevention Inspection First No.1081415339) in November 2019 for the implementation of field trials on dogs; meanwhile, Taipei City Animal Protection Office visited Gongwin Biopharm to complete the inspection and verification on special labels for animal trial production of drug samples (Animal Protection Inspection No. 1086026496); in February 2020, the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan, agreed to expand the field pre-test sites (Prevention Inspection First No 1091400445).

Caddie received seven Intratumoral injection treatments of "animal drug sample trial production of PTS", a total of 28.8mL.

After the malignant soft tissue sarcoma was injected intratumorally with "animal drug sample trial production of PTS", the swelling of drug liquid could be felt through palpation, little change on appearance. On the 13th day of treatment, black round scabs began to appear. Once the drug liquid was absorbed and metabolized, the volume of malignant soft tissue sarcoma returned to its original size and has not shrunken. After the completion of the 7th injections of "animal drug sample trial production of PTS", on the 28th day of the preliminary clinical trial treatment, the tissue fluid flew out of the damaged malignant soft tissue sarcoma autologously. After five times of debridement, the new normal granulation tissues on the hock joint appeared to be normal hyperplasia. After the surgical veterinarian fixed the wound and wrapped buffering external tubes, the volume of the hock joint was restored to the normal size to maintain normal walking function, and Caddie was sent back to Penghu.

(Before treatment)

Caddie's walking function was normal during the course of treatment and tumor debridement.

The Pet Medical Care Division is honored to have gained the trust of the owner, so Gongwin Biopharm can provide more treatment options for pets suffering from tumors. Gongwin Biopharm Pet Medical Care Division will continue to make every effort to contribute to the treatment of dogs suffering from tumors.